Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926)
…, TM Alvarez-Diez, J Hoyt, CN Woodward… - Journal of medicinal …, 2009 - ACS Publications
Recent evidence suggests that blocking aberrant hedgehog pathway signaling may be a
promising therapeutic strategy for the treatment of several types of cancer. Cyclopamine, a …
promising therapeutic strategy for the treatment of several types of cancer. Cyclopamine, a …
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90
…, MA Read, J Sang, C Woodward… - Proceedings of the …, 2006 - National Acad Sciences
Heat shock protein 90 (Hsp90) is an emerging therapeutic target of interest for the treatment
of cancer. Its role in protein homeostasis and the selective chaperoning of key signaling …
of cancer. Its role in protein homeostasis and the selective chaperoning of key signaling …
Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonists
…, MJ Campbell, J Cushing, CN Woodward… - Journal of medicinal …, 2008 - ACS Publications
Herein is reported the synthesis of a novel class of hedgehog antagonists derived from
cyclopamine. The acid sensitive D-ring of cyclopamine was homologated utilizing a sequence of …
cyclopamine. The acid sensitive D-ring of cyclopamine was homologated utilizing a sequence of …
Under the spotlight: understanding the role of the Chief Medical Officer in a pandemic
…, A Cassola, P Harris, C Woodward… - J Epidemiol …, 2022 - jech.bmj.com
As the COVID-19 pandemic took hold in 2020, Chief Medical Officers (CMOs) entered the
public spotlight like never before. Amidst this increased visibility, the role is deeply contested. …
public spotlight like never before. Amidst this increased visibility, the role is deeply contested. …
[HTML][HTML] Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans
YE Ye, CN Woodward, NI Narasimhan - Cancer chemotherapy and …, 2017 - Springer
Purpose Ponatinib is a novel tyrosine kinase inhibitor (TKI) specifically designed to inhibit
native and mutated BCR–ABL. In the United States, ponatinib has received accelerated …
native and mutated BCR–ABL. In the United States, ponatinib has received accelerated …
Phase II dose selection for alpha synuclein–targeting antibody cinpanemab (BIIB054) based on target protein binding levels in the brain
…, K Kandadi Muralidharan, C Woodward… - CPT …, 2020 - Wiley Online Library
This modeling and simulation analysis was aimed at selecting doses of cinpanemab (BIIB054),
a monoclonal antibody targeting aggregated α‐synuclein, for a phase II study in …
a monoclonal antibody targeting aggregated α‐synuclein, for a phase II study in …
Spatial distribution of spawning groupers on a Caribbean reef from an autonomous surface platform
C Woodward, M Schärer-Umpierre, RS Nemeth… - Fisheries …, 2023 - Elsevier
Many commercially important groupers (Epinephelidae) form fish spawning aggregations (FSA)
at specific sites where the spawning stock is concentrated to spawn within a couple of …
at specific sites where the spawning stock is concentrated to spawn within a couple of …
A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal …
…, JP Mendoza, B Zhu, T Plavina, C Woodward… - Multiple Sclerosis and …, 2021 - Elsevier
Background Biomarkers are a useful and reliable measure of disease activity in many fields
of medicine. Axonal and glial biomarkers in multiple sclerosis (MS) are being applied more …
of medicine. Axonal and glial biomarkers in multiple sclerosis (MS) are being applied more …
In vitro metabolism of BIIB021, an inhibitor of heat shock protein 90, in liver microsomes and hepatocytes of rats, dogs, and humans and recombinant human …
L Xu, C Woodward, S Khan, C Prakash - Drug Metabolism and Disposition, 2012 - ASPET
Inhibition of heat shock protein 90 (HSP90) results in the degradation of oncoproteins that
drive malignant progression and induce cell death, thus making HSP90 a potential target of …
drive malignant progression and induce cell death, thus making HSP90 a potential target of …
Metabolism and excretion of 6-chloro-9-(4-methoxy-3, 5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine, an HSP90 inhibitor, in rats and dogs and assessment of its …
L Xu, C Woodward, J Dai, C Prakash - Drug Metabolism and Disposition, 2013 - ASPET
6-Chloro-9-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-9H-purin-2-ylamine (BIIB021), a
synthetic HSP90 inhibitor, exhibited promising antitumor activity in preclinical models and was …
synthetic HSP90 inhibitor, exhibited promising antitumor activity in preclinical models and was …